British Columbia Investment Management Corp Nektar Therapeutics Transaction History

British Columbia Investment Management Corp

$16 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$15.87 - $23.12 $379,388 - $552,706	-23,906 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $533,375 - $1.14 Million	-31,542 Reduced 56.89%	23,906 $435,000
Q2 2019 Aug 12, 2019	BUY	$31.0 - $36.3 $366,048 - $428,630	11,808 Added 27.06%	55,448 $1.97 Million
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $6,284 - $9,223	199 Added 0.46%	43,640 $1.47 Million
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $700,468 - $1.3 Million	-23,019 Reduced 34.64%	43,441 $1.43 Million
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $839,857 - $1.24 Million	18,077 Added 37.36%	66,460 $4.05 Million
Q2 2018 Aug 09, 2018	BUY	$46.25 - $104.45 $2.24 Million - $5.05 Million	48,383 New	48,383 $2.36 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.

Account